Holen Sie sich die Stockscreener-App
3.49
2.79%
-0.10
Vorhandelsmarkt:
3.50
0.010
+0.29%
Schlusskurs vom Vortag:
$3.59
Offen:
$3.5
24-Stunden-Volumen:
543.82K
Relative Volume:
1.10
Marktkapitalisierung:
$130.78M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
-1.358
EPS:
-2.57
Netto-Cashflow:
$-67.42M
1W Leistung:
-5.93%
1M Leistung:
-19.77%
6M Leistung:
-54.14%
1J Leistung:
-83.21%
1-Tages-Spanne:
$3.42
$3.59
1-Wochen-Bereich:
$3.42
$3.985
52-Wochen-Spanne:
$3.42
$21.00
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
3.49 | 130.78M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
Nevro stock plunges to 52-week low at $3.51 amid market challenges - Investing.com
Nevro stock plunges to 52-week low at $3.51 amid market challenges By Investing.com - Investing.com South Africa
Director Weatherman Elizabeth H was granted 5,325 shares, increasing direct ownership by 7% to 86,171 units (SEC Form 4) - Quantisnow
State Street Corp Has $4.21 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
What Makes Nevro (NVRO) a New Buy Stock - Yahoo Finance
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - The Eastern Progress Online
Nevro price target lowered to $4.70 from $7 at Truist - Yahoo Finance
Where Nevro Stands With Analysts - Benzinga
Truist Financial Has Lowered Expectations for Nevro (NYSE:NVRO) Stock Price - MarketBeat
Nevro announces new inducement grants - Medical Buyer
Nevro Corp. (NYSE:NVRO) Receives $8.05 Consensus Target Price from Analysts - MarketBeat
Here's Why You Should Retain Nevro Stock In Your Portfolio Now - Barchart
Nevro shares price target cut, neutral stance held on potential By Investing.com - Investing.com South Africa
Nevro shares price target cut, neutral stance held on potential - Investing.com
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Nasdaq
Nevro Corp (NVRO) PT Lowered to $6 at Mizuho - StreetInsider.com
Nevro Corp's SWOT analysis: stock faces headwinds amid market challenges - Investing.com India
Nevro stock plunges to 52-week low, touches $3.95 By Investing.com - Investing.com South Africa
Nevro stock plunges to 52-week low, touches $3.95 - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 566,462 Shares of Nevro Corp. (NYSE:NVRO) - MarketBeat
Zacks.com featured highlights include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Jacobs Levy Equity Management Inc. Buys 246,979 Shares of Nevro Corp. (NYSE:NVRO) - MarketBeat
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - The Eastern Progress Online
Western Standard LLC Makes New $5.47 Million Investment in Nevro Corp. (NYSE:NVRO) - MarketBeat
Shay Capital LLC Increases Stake in Nevro Corp: A Strategic Move Amidst Financial Challenges - GuruFocus.com
Nevro Corp's SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com Canada
Nevro Corp's SWOT analysis: stock faces headwinds amid SCS market challenges By Investing.com - Investing.com South Africa
SVP, Chief Financial Officer Macleod Roderick H. covered exercise/tax liability with 816 shares, decreasing direct ownership by 0.61% to 133,118 units (SEC Form 4) - Quantisnow
SVP, Chief Operating Officer Christoforou Christofer covered exercise/tax liability with 583 shares, decreasing direct ownership by 0.42% to 138,399 units (SEC Form 4) - Quantisnow
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - AOL
Morgan Stanley Maintains Positive MedTech Outlook… - Inkl
Morgan Stanley slashes Nevro stock target, flags SCS struggles and strategic challenges - Investing.com Canada
What Analysts Are Saying About Nevro Stock - Inkl
Morgan Stanley slashes Nevro stock target, flags SCS struggles and strategic challenges By Investing.com - Investing.com South Africa
Nevro (NYSE:NVRO) Downgraded to "Underweight" Rating by Morgan Stanley - MarketBeat
Morgan Stanley Downgrades Nevro Corp (NVRO) to Underweight - StreetInsider.com
Nevro downgraded to Underweight from Equal Weight at Morgan Stanley - TipRanks
Fred Alger Management LLC Has $93,000 Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
Nevro (NVRO) Shares Outstanding (EOP) : 37.4 Mil (As of Sep. 2024) - GuruFocus.com
Engaged Capital LLC Has $13.66 Million Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
NVRO Stock Declines Despite Positive Study Data of Nevro1 System - MSN
Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):